Medrio
Medrio is recorded as a service provider in 29 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 29 trials · Latest update first
A Phase 3, Multi-Site, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of eRapa to Improve Clinical Outcomes in Participants with Familial Adenomatous Polyposis
Sponsor Biodexa Limited
- Start (EU)
- Latest update
- Estimated end
An Open-label Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung Disease
Sponsor United Therapeutics Corp.
- Start (EU)
- Latest update
- Estimated end
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy.
Sponsor Praxis Precision Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
The ADAPT Study: An Open-label, Long-term Safety Study of INZ-701 in Patients with ENPP1 Deficiency and ABCC6 Deficiency
Sponsor Inozyme Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
The ENERGY Study: An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (ENPP1) Deficiency or ATP-binding Cassette Sub-family C Member 6 (ABCC6) Deficiency
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
The ENERGY 2 Study: An Open-Label Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
Sponsor Inozyme Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
Sponsor Adarx Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 as monotherapy and in combination in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer
Sponsor Ellipses Pharma Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2 study of alisertib in combination with endocrine therapy in patients with HR+, HER2-negative recurrent or metastatic breast cancer
Sponsor Puma Biotechnology Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
Sponsor Elevara Medicines Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Sponsor Adarx Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
HELIOS: An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP).
Sponsor Disc Medicine Inc.
- Start (EU)
- Latest update
- Estimated end
An open label, pharmacokinetic and safety study of Combogesic® IV in pediatric patients with acute pain.
Sponsor Aft Pharmaceuticals Limited
- Start (EU)
- Latest update
- Estimated end
STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Sponsor Adarx Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A phase 2B, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of Rezpegaldesleukin in the treatment of severe to very severe alopecia areata in adult patients (Rezolve AA)
Sponsor Nektar Therapeutics
- Start (EU)
- Latest update
- Estimated end
The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
Sponsor Inozyme Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)
Sponsor United Therapeutics Corp.
- Start (EU)
- Latest update
- Estimated end
Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults with Hereditary Angioedema (HAE)
Sponsor Intellia Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than 18 years of Age with Autosomal Recessive Polycystic Kidney Disease (ARPKD).
Sponsor Otsuka Pharmaceutical Development & Commercialization Inc.
- Start (EU)
- Latest update
- Estimated end
An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis
Sponsor Tg Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Medrio?
The 2026-10-09 snapshot links Medrio to 29 distinct CTIS trials. Recorded services include Electronic data capture, Interactive response technology (IRT), Data management, Clinical outcome assessments, among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Medrio?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Immunology, Metabolic Disorders, Allergy. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Medrio conducted?
The linked trials record locations in 17 countries, including Spain, Germany, France, Italy, Poland. These are trial locations, not confirmed office locations or countries where Medrio delivered services.
What can this page tell me about Medrio's trial experience?
Browse 29 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Medrio. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Medrio Inc.